Eclipsemed establishes new manufacturing and international sales entity

NewsGuard 100/100 Score

Eclipsemed Ltd., a leading national supplier of advanced medical and aesthetic equipment, has announced the formation of Eclipse Global, its new manufacturing and international sales entity. Eclipse Global has acquired the controlling assets of Enlighten Medical Technologies, an Amsterdam-based company which manufacturers intense pulsed light and various laser technologies.

Tom O'Brien, CEO of Eclipsemed will also assume the role of Chief Executive Officer for Eclipse Global. Both companies will be headquartered in Dallas, Texas. Joining Eclipse Global as Chairman of the Board is Raz Avner, former CEO of Lumenis from 2003-2007. Ron Zakai, founder of Enlyten Medical Technologies, will join Eclipse Global as a consultant for the company.

"Eclipse, as a result of the Enlyten acquisition, is now positioned to control its destiny like never before," says Tom O'Brien CEO Eclipsemed and Eclipse Global. "Instead of waiting for the next big idea to come our way, we look forward to delivering those ideas from within, utilizing our talented organization. Eclipse is pleased to have moved successfully from a regional to a national distributor. We look forward to the future and establishing our goal of becoming a leading global aesthetic device manufacturer."

"As a research and development based company, Enlyten found itself with a significant portfolio of products and limited capacity for sales distribution," says Ron Zakai, Enlyten founder. "After researching distribution options, we were pleased to have found Eclipse, based in the United States. To duplicate the infrastructure Eclipse had already created would have required an intense investment for Enlyten. With such a realization in mind, both companies concluded our mutual strengths would be enhanced by becoming one. We are very excited to be a part of the Eclipse Global team as we prepare for several product launches in 2010."

Source:

Eclipsemed Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Navigating the complexities of controlled release drug formulations